Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: a cross-sectional analysis

BMC Research Notes

John A Spertus²  Fengming Tang²  Paul S Chan²  James H O'Keefe²  John H Lee²  Rajyalakshmi Gadi¹  James B Wetmore³ 

[1] Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, KS, USA;Department of Cardiovascular Outcomes Research, Saint Luke's Mid America Heart Institute, Kansas City, MO, USA;University of Kansas Medical Center, MS 3002, 3901 Rainbow Blvd, Kansas City, KS 66160, USA

关键词: Acute myocardial infarction;    N-terminal proBNP;    Vitamin D;   

Others  :  1166872
DOI  :  10.1186/1756-0500-4-542

 received in 2011-10-28, accepted in 2011-12-15,  发布年份 2011

【 摘 要 】

Background

Nutritional vitamin D deficiency is an emerging risk factor for acute myocardial infarction (AMI) and heart failure. The association of 25-hydroxyvitamin D levels with N-terminal pro B-type natriuretic peptide (NT-proBNP), a robust prognostic marker for post-AMI mortality and heart failure, is unknown and could illuminate a potential pathway for adverse outcomes among post-AMI patients with 25-hydroxyvitamin D deficiency.

Methods

In a cross-sectional analysis, we studied 238 AMI patients from 21 U.S. centers to test the association of nutritional vitamin D (25-hydroxyvitamin D [25(OH)D]) deficiency with NT-proBNP levels. Levels of 25(OH)D levels were categorized as normal (≥30 ng/mL), insufficient (>20 - <30 ng/mL), deficient (>10 - ≤20 ng/mL), or severely deficient (≤10 ng/mL).

Results

Low 25(OH)D levels were found in 95.7% of AMI patients. No significant trends for higher mean baseline log NT-proBNP levels in severely deficient (6.9 ± 1.3 pg/mL), deficient (6.9 ± 1.2 pg/mL), and insufficient (6.9 ± 0.9 pg/ml) groups were observed as compared with patients having normal (6.1 ± 1.7 pg/mL) levels, P = 0.17. Findings were similar in the subset of patients who had follow-up NT-proBNP levels drawn at one month. In multivariate regression modeling, after adjusting for multiple covariates, 25(OH)D was not associated with NT-proBNP.

Conclusions

Potential associations between nutritional vitamin D deficiency and prognosis in the setting of AMI are unlikely to be mediated through NT-proBNP pathways. Future studies should examine other mechanisms, such as inflammation and vascular calcification, by which 25(OH)D deficiency could mediate adverse outcomes post-AMI.

【 授权许可】

   
2011 Wetmore et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF: Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008, 52:1949-1956.
• [2]Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K: Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007, 167:1159-1165.
• [3]Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS: Hypovitaminosis D in medical inpatients. N Engl J Med 1998, 338:777-783.
• [4]Giovannucci E, Liu Y, Hollis BW, Rimm EB: 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008, 168:1174-1180.
• [5]Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003, 41:105-112.
• [6]Weishaar RE, Kim SN, Saunders DE, Simpson RU: Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990, 258:E134-142.
• [7]Weishaar RE, Simpson RU: Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol 1987, 253:E675-683.
• [8]Zittermann A, Schleithoff SS, Koerfer R: Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Fail Rev 2006, 11:25-33.
• [9]The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators J Clin Epidemiol 1988, 41:105-114.
• [10]Bidmon HJ, Gutkowska J, Murakami R, Stumpf WE: Vitamin D receptors in heart: effects on atrial natriuretic factor. Experientia 1991, 47:958-962.
• [11]Chen S, Nakamura K, Gardner DG: 1,25-dihydroxyvitamin D inhibits human ANP gene promoter activity. Regul Pept 2005, 128:197-202.
• [12]Weishaar RE, Simpson RU: The involvement of the endocrine system in regulating cardiovascular function: emphasis on vitamin D3. Endocr Rev 1989, 10:351-365.
• [13]Wu J, Garami M, Cao L, Li Q, Gardner DG: 1,25(OH)2D3 suppresses expression and secretion of atrial natriuretic peptide from cardiac myocytes. Am J Physiol 1995, 268:E1108-1113.
• [14]Singh NP, Sahni V, Garg D, Nair M: Effect of pharmacological suppression of secondary hyperparathyroidism on cardiovascular hemodynamics in predialysis CKD patients: A preliminary observation. Hemodial Int 2007, 11:417-423.
• [15]Bettencourt P, Ferreira A, Pardal-Oliveira N, Pereira M, Queiros C, Araujo V, Cerqueira-Gomes M, Maciel MJ: Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. Clin Cardiol 2000, 23:921-927.
• [16]Crilley JG, Farrer M: Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart 2001, 86:638-642.
• [17]Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003, 108:250-252.
• [18]Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996, 93:1963-1969.
• [19]Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald E: Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002, 89:463-465.
• [20]Bayes-Genis A, Lopez L, Zapico E, Cotes C, Santalo M, Ordonez-Llanos J, Cinca J: NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail 2005, 11:S3-8.
• [21]Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M: NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006, 27:330-337.
• [22]Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D: N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007, 71:548-554.
• [23]Roberts MA, Srivastava PM, Macmillan N, Hare DL, Ratnaike S, Sikaris K, Ierino FL: B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin J Am Soc Nephrol 2008, 3:1057-1065.
• [24]Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355:1126-1130.
• [25]Matias PJ, Ferreira C, Jorge C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A: 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 2009, 24:611-618.
• [26]Obineche EN, Saadi H, Benedict S, Pathan JY, Frampton CM, Nicholls MG: Interrelationships between B-type natriuretic peptides and vitamin D in patients on maintenance peritoneal dialysis. Perit Dial Int 2008, 28:617-621.
• [27]Moore C, Murphy MM, Keast DR, Holick MF: Vitamin D intake in the United States. J Am Diet Assoc 2004, 104:980-983.
• [28]Arnold SV, Chan PS, Jones PG, Decker C, Buchanan DM, Krumholz HM, Ho PM, Spertus JA: Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry. Circ Cardiovasc Qual Outcomes 4:467-476.
• [29]Lee JH, Gadi R, Spertus JA, Tang F, O'Keefe JH: Prevalence of vitamin D deficiency in patients with acute myocardial infarction. Am J Cardiol 107:1636-1638.
• [30]Arnold SV, Spertus JA, Jones PG, Xiao L, Cohen DJ: The impact of dyspnea on health-related quality of life in patients with coronary artery disease: results from the PREMIER registry. Am Heart J 2009, 157:1042-1049. e1041
• [31]Melamed ML, Michos ED, Post W, Astor B: 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168:1629-1637.
• [32]Zittermann A, Schleithoff SS, Koerfer R: Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005, 94:483-492.
• [33]Rossetti E, Mariani M, Poli A, Palmerini T, Finazzi S, Lotzniker M, Sangiorgi D, De Servi S: NT pro-B-type natriuretic peptide levels are related to microvascular reperfusion in patients undergoing direct percutaneous transluminal coronary angioplasty for anterior ST-segment elevation myocardial infarction. J Cardiovasc Med (Hagerstown) 11:359-364.
• [34]Murthy K, Stevens LA, Stark PC, Levey AS: Variation in the serum creatinine assay calibration: a practical application to glomerular filtration rate estimation. Kidney Int 2005, 68:1884-1887.
• [35]Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
• [36]Burg MM, Barefoot J, Berkman L, Catellier DJ, Czajkowski S, Saab P, Huber M, DeLillo V, Mitchell P, Skala J, et al.: Low perceived social support and post-myocardial infarction prognosis in the enhancing recovery in coronary heart disease clinical trial: the effects of treatment. Psychosom Med 2005, 67:879-888.
• [37]Mookadam F, Arthur HM: Social support and its relationship to morbidity and mortality after acute myocardial infarction: systematic overview. Arch Intern Med 2004, 164:1514-1518.
• [38]Rahimi AR, Spertus JA, Reid KJ, Bernheim SM, Krumholz HM: Financial barriers to health care and outcomes after acute myocardial infarction. Jama 2007, 297:1063-1072.
• [39]Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, Boehm BO, Dobnig H: Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008, 93:3927-3935.
• [40]Mueller T, Gegenhuber A, Poelz W, Haltmayer M: Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004, 341:41-48.
• [41]Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R: Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83:754-759.
• [42]de Lemos JA, Morrow DA: Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation 2002, 106:2868-2870.
• [43]Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E: Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003, 41:1264-1272.
• [44]Mistry N, Abdelnoor M, Seljeflot I, Hoffmann P, Bohmer E, Bjornerheim R, Kjeldsen SE, Halvorsen S: Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels 3 months after myocardial infarction are more strongly associated with magnetic resonance-determined ejection fraction than NTproBNP levels in the acute phase. J Card Fail 17:479-486.